Alastair Garfield

CIK: 0002027261

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)6 (40.0%)

Position reduction

Option Exercises (M)3 (20.0%)

Derivative conversions

Awards (A)4 (26.7%)

Compensation grants

Other (G, F, J, C, D, …)2 (13.3%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

RYTM

RHYTHM PHARMACEUTICALS, INC.

Officer

Discretionary Trading P&L

Holdings

Transaction History (15 total)

RYTM
RHYTHM PHARMACEUTICALS, INC.
Aug 13, 2026
Sale(S)
Direct
2K shares at avg. $116.11$233K
RYTM
RHYTHM PHARMACEUTICALS, INC.
Aug 13, 2026
Sale(S)
Direct
1.6K shares at avg. $117.08$182K
RYTM
RHYTHM PHARMACEUTICALS, INC.
Aug 13, 2026
Sale(S)
Direct
3.4K shares at avg. $118.28$402K
RYTM
RHYTHM PHARMACEUTICALS, INC.
Aug 13, 2026
Sale(S)
Direct
800 shares at avg. $119.17$95K
RYTM
RHYTHM PHARMACEUTICALS, INC.
Jul 1, 2026
Exercise(M)
Direct
4.4K shares-
RYTM
RHYTHM PHARMACEUTICALS, INC.
Jul 1, 2026
Tax Payment(F)
Direct
2.2K shares at avg. $110.41$237K
RYTM
RHYTHM PHARMACEUTICALS, INC.
Feb 11, 2026
Award(A)
Stock Options (Right to Buy)
Direct
25K shares-
RYTM
RHYTHM PHARMACEUTICALS, INC.
Feb 11, 2026
Award(A)
Restricted Stock Units
Direct
16.7K shares-
RYTM
RHYTHM PHARMACEUTICALS, INC.
Feb 1, 2026
Tax Payment(F)
Direct
2K shares at avg. $108.99$221K
RYTM
RHYTHM PHARMACEUTICALS, INC.
Feb 1, 2026
Exercise(M)
Direct
6.7K shares-
RYTM
RHYTHM PHARMACEUTICALS, INC.
Jul 2, 2025
Sale(S)
Direct
1.3K shares at avg. $64.81$85K
RYTM
RHYTHM PHARMACEUTICALS, INC.
Jul 2, 2025
Sale(S)
Direct
6 shares at avg. $64.60$387.6
RYTM
RHYTHM PHARMACEUTICALS, INC.
Jul 1, 2025
Exercise(M)
Direct
4.4K shares-
RYTM
RHYTHM PHARMACEUTICALS, INC.
Feb 14, 2025
Award(A)
Restricted Stock Units
Direct
26.7K shares-
RYTM
RHYTHM PHARMACEUTICALS, INC.
Feb 14, 2025
Award(A)
Stock Options (Right to Buy)
Direct
40K shares-

		Type	Shares	Price		Ownership
Aug 13, 2026	RYTM RHYTHM PHARMACEUTICALS, INC.	Sale(S)	2,007	$116.11	$233,031	Direct
Aug 13, 2026	RYTM RHYTHM PHARMACEUTICALS, INC.	Sale(S)	1,556	$117.08	$182,170	Direct
Aug 13, 2026	RYTM RHYTHM PHARMACEUTICALS, INC.	Sale(S)	3,400	$118.28	$402,167	Direct
Aug 13, 2026	RYTM RHYTHM PHARMACEUTICALS, INC.	Sale(S)	800	$119.17	$95,335	Direct
Jul 1, 2026	RYTM RHYTHM PHARMACEUTICALS, INC.	Exercise(M)	4,445	-	$0	Direct
Jul 1, 2026	RYTM RHYTHM PHARMACEUTICALS, INC.	Tax Payment(F)	2,150	$110.41	$237,382	Direct
Feb 11, 2026	RYTM RHYTHM PHARMACEUTICALS, INC.	Award(A) Stock Options (Right to Buy)	25,000	-	-	Direct
Feb 11, 2026	RYTM RHYTHM PHARMACEUTICALS, INC.	Award(A) Restricted Stock Units	16,650	-	-	Direct
Feb 1, 2026	RYTM RHYTHM PHARMACEUTICALS, INC.	Tax Payment(F)	2,026	$108.99	$220,814	Direct
Feb 1, 2026	RYTM RHYTHM PHARMACEUTICALS, INC.	Exercise(M)	6,663	-	$0	Direct
Jul 2, 2025	RYTM RHYTHM PHARMACEUTICALS, INC.	Sale(S)	1,313	$64.81	$85,096	Direct
Jul 2, 2025	RYTM RHYTHM PHARMACEUTICALS, INC.	Sale(S)	6	$64.60	$388	Direct
Jul 1, 2025	RYTM RHYTHM PHARMACEUTICALS, INC.	Exercise(M)	4,445	-	-	Direct
Feb 14, 2025	RYTM RHYTHM PHARMACEUTICALS, INC.	Award(A) Restricted Stock Units	26,650	-	-	Direct
Feb 14, 2025	RYTM RHYTHM PHARMACEUTICALS, INC.	Award(A) Stock Options (Right to Buy)	40,000	-	-	Direct

1-15 of 15 transactions

About Garfield Alastair

Garfield Alastair (SEC CIK 0002027261) files insider reports with the SEC as Chief Scientific Officer of RHYTHM PHARMACEUTICALS, INC. (RYTM).

Signal8 holds 6 ownership filings by Garfield Alastair, all Form 4s, filed between Feb 19, 2025 and Aug 17, 2026. Those filings report 15 transactions, from Feb 14, 2025 to Aug 13, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Garfield Alastair's filings is in BOSTON, MA.

Recent filings by Garfield Alastair

Aug 13, 2026: Open-market sales of RYTM shares (4 lines, Form 4, code S).
Jul 1, 2026: Option exercise of RYTM shares (Form 4, code M).
Jul 1, 2026: Tax withholding of RYTM shares (Form 4, code F).
Feb 11, 2026: Grants or awards of RYTM derivative securities (2 lines, Form 4, code A).
Feb 1, 2026: Tax withholding of RYTM shares (Form 4, code F).

Other insiders filing for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Meeker David P, President and CEO
Smith Hunter C, Chief Financial Officer
Joshi Manher, Chief Medical Officer
Shulman Joseph, Chief Technical Officer
Lee Jennifer Kayden, EVP, Head of North America
Mazabraud Yann, EVP, Head of International

How to read Form 4 transaction codes